부산대학교 도서관

In January 2019, the ABCD nationwide semaglutide audit was launched with the aim of providing real world evidence on semaglutide use in UK clinical practice. Methods: Data were extracted from the ABCD audit tools and included providing they had sufficient follow-up data. Data were analysed in Stata SE 16. A planned sub-analysis of those switched from any other glucagon like peptide receptor-1 agonist (GLP1-RA) was performed. Results: 1467 patient data sets were included with a mean±SD age 58.9 years ±11.1, weight 106.4kg ±23.2, BMI 36.8kg/m2 ±7.4, HbA1c 9.4% ±1.7 (79.1mmol/mol±18.6). This population is significantly different to the randomised control trial populations which had mean weight approx. 93kg and mean HbA1c approx. 8.2% (66mmol/mol). Median diabetes duration 10.6 years (IQR 5-14.7); 55.3% were male. The median follow-up period was 0.6years (IQR 0.4-0.8). In this cohort mean changes in HbA1c -1.2% (95% CI -1.1, -1.3) or -13.2mmol/mol (95% CI -11.8, -14.5) (P<0.0001), weight of -4.6kg (95% CI -3.9, -5.2; P<0.0001) and BMI -1.5kg/m2 (95% CI -1.3, -1.7, P<0.0001) were noted from baseline across the population as a whole. 319 (21.75%) were switched from an alternative GLP1-agonist. Further changes in HbA1c of -0.8% (95% CI -0.6, -1.0) or -7.8mmol/mol (95% CI -5.4, -10.1)(P<0.0001) and weight (-3.4kg; 95% CI -2.4, -4.3; P<0.0001) were noted following the switch to semaglutide. Conclusion: This early analysis demonstrates the differences between our real-world cohort and the more stringently controlled randomised control trial cohorts - in the UK semaglutide is being used in people with diabetes who are heavier and with higher HbA1c levels at baseline. Additional reductions in HbA1c and weight were observed in those switching from alternative GLP1-RAs. Disclosure: T. S. J. Crabtree: Other Relationship; Self; Novo Nordisk, Sanofi. R. E. Ryder: Other Relationship; Self; Novo Nordisk. A. Bickerton: None. D. K. Sennik: Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. A. Rohilla: None. S. Sivappriyan: None. D. Barnes: None. M. L. Cull: None. I. W. Gallen: None. K. Adamson: None. Funding: Association of British Clinical Diabetologists [ABSTRACT FROM AUTHOR]